Xeris Pharmaceuticals Inc Forecast, price target & analysts
Xeris Pharmaceuticals Inc Target price 2025 - Analyst rating & recommendation
Xeris Pharmaceuticals Inc Classifications & Recommendation:
Xeris Pharmaceuticals Inc Price Target
| Target Price | $5.10 |
| Price | $3.76 |
| Potential |
35.64%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Xeris Pharmaceuticals Inc 2026 .
The average Xeris Pharmaceuticals Inc target price is $5.10.
This is
35.64%
register free of charge
$6.60
75.53%
register free of charge
$3.00
20.21%
register free of charge
|
|
| A rating was issued by 6 analysts: 5 Analysts recommend Xeris Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Xeris Pharmaceuticals Inc stock has an average upside potential 2026 of
35.64%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 163.91 | 201.08 |
| 48.67% | 22.68% | |
| EBITDA Margin | -18.82% | -10.86% |
| 69.39% | 42.30% | |
| Net Margin | -40.91% | -30.38% |
| 56.76% | 25.73% |
6 Analysts have issued a sales forecast Xeris Pharmaceuticals Inc 2024 . The average Xeris Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Xeris Pharmaceuticals Inc EBITDA forecast 2024. The average Xeris Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Xeris Pharmaceuticals Inc Analysts have issued a net profit forecast 2024. The average Xeris Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.45 | -0.41 |
| 35.71% | 8.89% | |
| P/E | negative | |
| EV/Sales | 3.79 |
5 Analysts have issued a Xeris Pharmaceuticals Inc forecast for earnings per share. The average Xeris Pharmaceuticals Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Xeris Pharmaceuticals Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Xeris Pharmaceuticals Inc...
Current Xeris Pharmaceuticals Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 11 2024 |
| Piper Sandler | Locked ➜ Locked | Locked | Nov 11 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 11 2024 |
|
Locked
Piper Sandler: Locked ➜ Locked
|
Nov 11 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
